| Metric | Q3 FY26 | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Other income | 0.0 | 0.1 | 0.0 |
| Total income | 0.2 | 4.4 | 24.1 |
| Net profit | -0.1 | 0.4 | 0.1 |
| Operating margin | -50.0% | 9.1% | 0.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
BSE results filing, NSE: SRDAPRT. Figures extracted from the filing.
Fresita Proteins Ltd: key numbers
- Share price
- ₹142.63
- Market cap
- ₹128.0 Cr
- Revenue (annual)
- ₹16.16 Cr
- Net profit (annual)
- ₹0.64 Cr
- P/E (TTM)
- 45.9×Sector 42.2×
- Promoter holding
- 80.66%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Fresita Proteins Ltd
All →Sarda Proteins Price Movement Clarification
Sarda Proteins Limited responded to a BSE query regarding recent stock price movement. The company stated the fluctuations are driven by market forces and conditions.
Sarda Proteins Other Announcement
Sarda Proteins Limited has changed its name to Fresita Proteins Limited, effective September 21, 2026. The name change received approval from the Ministry of Corporate Affairs and BSE.
Sarda Proteins Annual Report
Sarda Proteins Limited filed its 35th Annual Report for the financial year ended 31st March 2026 with the stock exchange.
Sarda Proteins Annual General Meeting
Sarda Proteins set its 35th AGM for September 30, 2026, with book closure September 24–30. E-voting cut-off date is September 23, 2026.
Sarda Proteins Board Meeting Outcome
Sarda Proteins board approved convening its AGM on September 30, 2026, along with e-voting, scrutinizer, and register-closure arrangements. No financial or operational decisions were taken.
Fresita Proteins Board Meeting Date
Sarda Proteins Limited has scheduled a board meeting for September 7, 2026. The agenda includes approval for the upcoming Annual General Meeting and associated administrative matters.